Spruce Biosciences Inc. has announced that it has received conditional approval to resume trading on the Nasdaq Capital Market, where its common stock had been temporarily suspended. The trading resumption is contingent upon meeting Nasdaq's minimum bid price requirement by August 5, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.